«上一篇/Previous Article|本期目录/Table of Contents|下一篇/Next Article»

《中华肺部疾病杂志》[ISSN:1006-6977/CN:61-1281/TN]

卷:

期数:

2021年02期

页码:

195-197

栏目:

临床研究

出版日期:

2021-04-20

文章信息/Info

Title:

-

作者:

甘丽杏¹ 熊维宁¹ 郭雪君²

200011 上海,上海交通大学医学院附属第九人民医院呼吸内科¹ 200000 上海, 上海交通大学医学院附属新华医院呼吸内科²

Author(s):

-

关键词:

肺疾病; 慢性阻塞性;  肿瘤坏死因子-α;  白介素-8;  白介素-6;  组蛋白去乙酰化酶2;  姜黄素;  激素抵抗

Keywords:

-

分类号:

R563

DOI:

10.3877/cma.j.issn.1674-6902.2021.02.012

摘要:

目的 分析慢性阻塞性肺疾病(COPD)急性加重期与稳定期患者相比,肿瘤坏死因子(TNF-α)、IL-8及IL-6以及组蛋白去乙酰化酶2(HDAC2)表达。进一步明确姜黄素、地塞米松等药物体外干预对COPD急性加重期(AECOPD)血液中三种炎症因子以及HDAC2表达影响。方法 选取对照、稳定期COPD及AECOPD 3组每组10例,入院次日抽取空腹静脉血,分为AECOPD对照组、姜黄素共培养组、地塞米松共培养组、姜黄素+地塞米松共培养组,培养24 h。酶联免疫吸附法(ELISA)检测炎症因子及HDAC2表达。 结果 按照对照组、COPD稳定期组及AECOPD组,TNF-α表达分别为(22.0±3.5)pg/ml,(50.0±4.7)pg/ml,(110.3±6.7)pg/ml; IL-8表达分别为(49.0±5.0)pg/ml,(99.5±9.2)pg/ml,(202.0±15.8)pg/ml; IL-6表达分别为(21.5±4.4)pg/ml,(80.3±7.3)pg/ml,(114.0±9.5)pg/ml; 与对照组相比,稳定期COPD组与AECOPD组三种炎症因子表达有意义(P<0.01)。HDAC2表达水平按照分组情况分别为(8.5±0.5)pg/ml,(6.8±0.5)pg/ml,(2.5±0.5)pg/ml。HDAC2表达按照分组逐渐减低,且炎症因子表达升高与HDAC2表达降低呈负相关,相关系数分别是r=-0.309,r=-0.067,r=-0.244,P<0.01。培养组按照AECOPD对照组、姜黄素培养组、地塞米松培养组、姜黄素+地塞米松共培养分组,TNF-α的表达分别为(101.5±6.6)pg/ml,(91.6±14.7)pg/ml,(87.0±14.1)pg/ml,(53.6±9.1)pg/ml; IL-8表达分别为(116.5±13.2)pg/ml,(99.4±9.7)pg/ml,(94.3±10.1)pg/ml,(72.1±15.1)pg/ml; IL-6表达分别为(96.4±9.0)pg/ml,(86.0±10.5)pg/ml,(82.8±9.4)pg/ml,(71.2±6.9)pg/ml。姜黄素+地塞米松共培养组炎症因子表达较单用地塞米松组明显减低,P<0.01; HDAC2按照分组表达分别为:(2.2±0.5)pg/ml,(3.4±0.8)pg/ml,(3.5±0.5)pg/ml,(7.1±0.9)pg/ml,姜黄素+地塞米松共培养组HDAC2表达较单用地塞米松组高,P<0.01。结论 AECOPD患者TNF-α、IL-8、IL-6表达均较稳定期增加,姜黄素及地塞米松均能降低炎症因子表达,当姜黄素与地塞米松共培养后,降低炎症因子表达,提高HDAC2蛋白表达,姜黄素可能是通过HDACs通路,活化HDAC2,抑制炎症基因表达,为COPD激素抵抗治疗药物应用有意义。

Abstract:

-

参考文献/References:

1 任成山, 王关嵩, 钱桂生. 慢性阻塞性肺疾病的成因及其治疗的困惑与希望[J/CD]. 中华肺部疾病杂志(电子版), 2019, 12(2): 127-141.
2 Adcock IM, Tsaprouni L, Bhavsar P, et al. Epigenetic regulation of airway inflammation[J]. Curr Opin Immunol, 2007, 19(6): 694-700.
3 Tamimi A, Serdarevic D, Hanania NA. The effects of cigarette smoke on airway inflammation in asthma and COPD: therapeutic implications[J]. Respir Med, 2012, 106(3):319-328.
4 Cheng SE, Luo SF, Jou MJ, et al. Cigarette smoke extract induces cytosolic phospholipase A2 expression via NADPH oxidase, MAPKs, AP-1, and NF-kappaB in human tracheal smooth muscle cells[J]. Free Radic Biol Med, 2009, 46(7): 948-960.
5 Gan LX, Li CY, Guo XJ, et al. Curcumin modulates the effect of histone modification on the expression of chemokines by type Ⅱ alveolar epithelial cells in a rat COPD model[J]. Int J Chron Obstruct Pulmon Dis, 2016, 11: 2765-2773.
6 甘丽杏, 李成业, 郭雪君. 慢性阻塞性肺疾病组蛋白去乙酰化酶与糖皮质激素抵抗[J]. 国际呼吸杂志, 2010, 30(5): 283-285.
7 Barnes PJ. Corticosteroid resistance in patients with asthma and chronic obstructive pulmonary disease[J]. J Allergy Clin Immunol, 2013, 131(3): 636-645.
8 Meja KK, Rajendrasozhan S, Adenuga D, et al. Curcumin Restores Corticosteroid Function in Monocytes Exposed to Oxidants by Maintaining HDAC2[J]. Am J Respir Cell Mol Biol, 2008, 39(3): 312-323.
9 Barnes PJ. Role of HDAC2 in the pathophysiology of COPD[J]. Annu Rev Physiol, 2009, 71: 451-464.
10 Zhang M, Xie Y, Yan R, et al. Curcumin ameliorates alveolar epithelial injury in a rat model of chronic obstructive pulmonary disease[J]. Life Sci, 2016, 1(164): 1-8.
11 Tang F, Ling C. Curcumin ameliorates chronic obstructive pulmonary disease by modulating autophagy and endoplasmic reticulum stress through regulation of SIRT1 in a rat model[J]. J Int Med Res, 2019, 47(10): 4764-4774.
12 Barnes PJ, Adcock IM. Glucocorticoid resistance in inflammatory diseases[J]. Lancet, 2009, 373(9678): 1905-1917.
13 中华医学会呼吸病学慢性阻塞性肺疾病组. 慢性阻塞性肺疾病诊治指南(2007年修订版)[J].中华内科杂志, 2007, 46(43): 254-261.
14 慢性阻塞性肺疾病急性加重(AECOPD)诊治专家组[J]. 国际呼吸杂志, 2017, 37(14): 1041-1057
15 Seemungal TA, Harper-owen R, Bhowmik A, et al. Detection of rhinovirus in induced sputum at exacerbation of chronic obstructive pulmonary disease[J]. Eur Respir J, 2000, 16(4): 677-683.
16 杨 阳, 杨 雁. COPD缓解期患者血清PCT、IL-6、hs-CRP水平对急性加重的预测作用[J]. 广东医学, 2017, 38(10): 1531-1533.
17 王 飞, 贺 蓓. 组蛋白去乙酰化酶在慢性阻塞性肺疾病中的重要作用[J]. 国际呼吸杂志, 2007, 27(13): 985-988.
18 Ito K, Jazrawi E, Cosio B, et al. p65-activated histone acetyltransferase activity is repressed by glucocorticoids: mifepristone fails to recruit HDAC2 to the p65-HAT complex[J]. J Biol Chem, 2001, 276(32): 30208-30215.
19 Rahman I, Adcock IM. Oxidative stress and redox regulation of lung inflammation in COPD[J]. Eur Respir J, 2006, 28(1): 219-242.
20 Ito K, Chung KF, Adcock IM. Update on glucocorticoid action and resistance[J]. Allergy Clin Immunol, 2006, 117(3): 522-543.
21 Hull EE, Montgomery MR, Leyva KJ. HDAC2 inhibitors as epigenetic regulators of the immune system: impacts on cancer therapy and inflammatory diseases[J]. Biomed Res Int, 2016, 2016: 8797206.
22 Ito K, Ito M, Elliott WM, et al. Decreased histone deacetylase activity in chronic obstructive pulmonary disease[J]. N Engl J Med, 2005, 352(19): 1967-1976.
23 Barnes P, Ito K, Adcock IM. A mechanism of corticosteroid resistance in COPD: inactivation of histone deacetylase[J]. Lancet, 2004, 363(9410): 731-733.

备注/Memo

备注/Memo:

课题基金: 上海高校青年教师培养资助计划(ZZjdyx13101)
通信作者: 郭雪君, Email: guoxjz@yahoo.com.cn

常用功能

更新日期/Last Update: 2021-04-20